Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.71 |
| ▸ | TRPC1 | P48995 | 2/20 | 0.61 |
| ▸ | TRPC3 | Q13507 | 2/20 | 0.61 |
| ▸ | STIM1 | Q13586 | 2/20 | 0.61 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.61 |
| ▸ | STIM2 | Q9P246 | 2/20 | 0.61 |
| ▸ | ACHE | P22303 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.51 |
| ▸ | HPGD | P15428 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21419596 | 0.86 | TRPC1 (0.68) | MAPTTRPC1TRPC3STIM1ORAI1 | |
| SCHEMBL1194642 | 0.85 | TRPC1 (0.67) | MAPTTRPC1TRPC3STIM1ORAI1 | |
| SCHEMBL13519243 | 0.85 | MAPT (0.78) | MAPTL3MBTL1HTTHPGDALDH1A1 | |
| SCHEMBL8345184 | 0.85 | TRPC1 (0.67) | MAPTTRPC1TRPC3STIM1ORAI1 | |
| SCHEMBL2325526 | 0.84 | MAPT (0.76) | MAPTTRPC1TRPC3STIM1ORAI1 | |
| SCHEMBL5533620 | 0.84 | TRPC1 (0.66) | MAPTTRPC1TRPC3STIM1ORAI1 | |
| SCHEMBL19692480 | 0.84 | TRPC1 (0.66) | MAPTTRPC1TRPC3STIM1ORAI1 | |
| SCHEMBL1814204 | 0.83 | ALDH1A1 (0.67) | MAPTTRPC1TRPC3STIM1ORAI1 | |
| SCHEMBL31000766 | 0.83 | MAPT (1.00) | MAPTL3MBTL1HTTHPGDALDH1A1 | |
| SCHEMBL12931795 | 0.83 | TRPC1 (0.66) | MAPTTRPC1TRPC3STIM1ORAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265068-A1 | TRANSIENT RECEPTOR POTENTIAL CANONICAL 3 INHIBITORS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230265068-A1 | TRANSIENT RECEPTOR POTENTIAL CANONICAL 3 INHIBITORS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2023-08-24 | — | — | US | disclosed |
| WO-2022081573-A1 | TRANSIENT RECEPTOR POTENTIAL CANONICAL 3 INHIBITORS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3468964-B1 | MODULATORS OF SOCE, COMPOSITIONS, AND USES THEREOF | UNIV DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO (IT) | 2020-12-30 | — | — | EP | disclosed |
| US-20190300509-A1 | MODULATORS OF SOCE, COMPOSITIONS, AND USES THEREOF | UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE "AMEDEO AVOGADRO" (IT) | 2019-10-03 | — | — | US | disclosed |
| EP-3468964-A1 | MODULATORS OF SOCE, COMPOSITIONS, AND USES THEREOF | Università degli Studi del Piemonte Orientale "Amedeo Avogadro" (IT) | 2019-04-17 | — | — | EP | disclosed |
| WO-2017212414-A1 | MODULATORS OF SOCE, COMPOSITIONS, AND USES THEREOF | UNIVERSITÀ DEGLI STUDI DEL PIEMONTE ORIENTALE "AMEDEO AVOGADRO" (IT) | 2017-12-14 | — | — | WO | disclosed |
| US-7087634-B2 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (US) | 2006-08-08 | — | — | US | disclosed |
| US-20030236412-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION | 2003-12-25 | — | — | US | disclosed |
| US-6569885-B1 | Such as 1-(4-bromophenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylic acid ethyl ester; side effect reduction; for treatment of central nervous system disorders | ICOS CORPORATION | 2003-05-27 | — | — | US | disclosed |
| EP-1248781-A1 | PYRAZOLE CYCLIC AMP-SPECIFIC PDE INHIBITORS | ICOS CORPORATION (US) | 2002-10-16 | — | — | EP | disclosed |
| WO-2001046172-A1 | PYRAZOLE CYCLIC AMP-SPECIFIC PDE INHIBITORS | ICOS CORPORATION (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300509-A1 | MODULATORS OF SOCE, COMPOSITIONS, AND USES THEREOF | STIM1, ORAI1, SARAF | MAPT 2717/4885TRPC1 11/4885TRPC3 12/4885 |
| US-20230265068-A1 | TRANSIENT RECEPTOR POTENTIAL CANONICAL 3 INHIBITORS AND METHODS OF USE THEREOF | TRPC3, TRPV3, TRPV1 | MAPT 2823/4885TRPC1 5/4885TRPC3 1/4885 |
| US-20030236412-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | PDE4A, PDE4B, PDE7A | MAPT 2234/4885TRPC1 3392/4885TRPC3 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.